The anti-NASH effect of ACC1 inhibitors alone or in combination with ACC1 inhibitors (PF-05221304) and diacylglycerol acyltransferase 2 (DGAT2) inhibitors (PF-06865571) has been tested in a clinical trial (Calle et al., 2021). Here, DGAT2 is linked to metabolic dysfunction-associated steatohepatitis.